Evidence map›Paper›PMID 40260378›Full record

ReviewFrontiers in pharmacology2025

The outcast of medicine: metals in medicine--from traditional mineral medicine to metallodrugs.

Donghan Bai, Michal Nowak, Dajun Lu, Qiaochu Wang, Martin Fitzgerald, Hui Zhang, Remy MacDonald, Ziwen Xu, Lu Luo

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Donghan BaiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Michal NowakFaculty of Medicine, Poznan University of Medical Sciences, Poznan, Poland.
Dajun LuCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Qiaochu WangDepartment of Biochemistry and Molecular and Cellular Biology, Georgetown University, Washington, DC, United States.
Martin FitzgeraldAshdale Clinic, Cork, Ireland.
Hui ZhangInstitute of Traditional Chinese Medicine, European University of Chinese Medicine, Horsens, Denmark.
Remy MacDonaldDepartment of Statistics, George Mason University, Virginia, VA, United States.
Ziwen XuDepartment of Nursing, The University of Melbourne, Parkville, VIC, Australia.
Lu LuoInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FRANCESCA M GANY · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Metals have long held a significant role in the human body and have been utilized as mineral medicines for thousands of years. The modern advancement of metals in pharmacology, particularly as metallodrugs, has become crucial in disease treatment. As the machanism of metallodurgsare increasingly uncovered, some metallodrugs are already approved by FDA and widely used in treating antitumor, antidiabetes, and antibacterial. Therefore, a thorough understanding of metallodrug development is essential for advancing future study. This review offers an in-depth examination of the evolution of mineral medicines and the applications of metallodrugs within contemporary medicine. We specifically aim to summarize the historical trajectory of metals and mineral medicines in Traditional Chinese Mineral Medicine by analyzing key historical texts and representative mineral medicines. Additionally, we discuss recent advancements in understanding metallodrugs' mechanisms, such as protein interactions, enzyme inhibition, DNA interactions, reactive oxygen species (ROS) generation, and cellular structure targeting. Furthermore, we address the challenges in metallodrug development and propose potential solutions. Lastly, we outline future directions for metallodrugs to enhance their efficacy and effectiveness. The progression of metallodrugs has broadened their applications and contributed significantly to patient health, creating good healthcare solutions for the global population.

Indexed as

anticancerinorganic medicineintegrative medicinemetallodrugmineral medicinetraditional Chinese medicine

Identifiers

PMID40260378
PMCPMC12010122

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.